Fr1da Daten Analyse

• Teplizumab to delay stage 3 type 1 diabetes: Generalizability of the TN-10 trial to a European population (Julia Zaccai, Sanofi Winthrop Industrie, Paris, Frankreich; Thermo Fisher Scientific (Evidera), Ivry-Sur-Seine, Frankreich; Evidera Ltd, London, UK; School of Immunology and Microbial Sciences, Kings College, London, UK)

• BEYOND STAGES OF T1D: Exploring risk modeling across datasets (cross-validate three models to predict individualized risk for T1D progression using the Fr1da data set) (Prof. Dr. Carla Greenbaum, Benaroya Research Institute at Virginia Mason, Seattle, USA)

• Pilot study to test the hypothesis that the frequency of 127-hi Th2, and levels of expression of Th2-associated genes correlates with the speed of disease progression before diabetes onset in children participating in the Fr1da-study. (Prof. Dr. Joanna Davis, Ballad Research Institute, San Diego, UK)

Messungen und Analysen aus Fr1da Biobankproben

• Determine the capacity of DNA methylation (DNAm) in peripheral blood to predict progression from stage 1 to stage 3 relative type 1 diabetes ( Prof. Dr. Caroline Relton, University of Bristol, UK)
• Viral infections as trigger of rapid progression to type 1 diabetes (Prof. Dr. Anette-Gabriele Ziegler, Helmholtz Munich)
• Characterization of autoantibody epitope binding and genetic profile in Fr1da children with early stage T1D (stage 1 and 2) compared to children at clinical manifestation (stage 3)  (Prof. Dr. Anette-Gabriele Ziegler, Helmholtz Munich)